New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
08:51 EDTLBIOLion Biotechnologies deal increases visibility, says Roth Capital
After Lion Biotechnologies (LBIO) and Immunocore entered into an agreement to co-discover and co-develop novel T-cell based cancer therapies. Roth Capital thinks the deal increases the visibility for T-cell therapies and is positive for Lion Biotechnologies. The firm sees the deal as an indication that large drug companies remain interested in the T-cell based immunotherapy space, and it thinks that Lion is well-positioned in the space. The firm reiterates a $20 price target and Buy rating on Lion.
News For LBIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
09:26 EDTLBIOOn The Fly: Pre-market Movers
Subscribe for More Information
08:59 EDTLBIOLion Biotech has positive read through from Celgene deal, says Roth Capital
Subscribe for More Information
07:03 EDTLBIOCelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
June 29, 2015
19:01 EDTLBIOOn The Fly: After Hours Movers
HIGHER: Juno Therapeutics (JUNO), up 38.4% after announcing immunotherapy collaboration with Celgene (CELG)... Kite Pharma (KITE) and Lion Biotechnologies (LBIO) are up 8.7% and 5.7% respectively, following Juno's collaboration with Celgene. DOWN AFTER EARNINGS: CHC Group (HELI), down 8%... Apollo Education (APOL), down 6.2%. ALSO LOWER: EnteroMedics (ETRM), down 12.4% after filing to sell common stock and warrants... Celgene (CELG), down 1% after Juno announces immunotherapy collaboration.
18:09 EDTLBIOJuno surges after Celgene collaboration, CAR-T peers follow
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use